NCT01652690COMPLETEDanonymous

Prospective Observational Study to Describe Characteristics and Management of Patients With Postmenopausal Osteoporosis Treated With Prolia® in Routine Clinical Practice

Sponsor

Source record

Amgen

Phase

Source record

Observational

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Denosumab (Prolia®)

Indication / condition

AI-normalized

Osteoporosis, Postmenopausal

Intervention

Source record

Denosumab

Related intelligence directories

Indication directory: Osteoporosis Modality directory: monoclonal antibody Target directory: Denosumab (Prolia®)

Source & freshness

Source record

NCT ID

NCT01652690

Original source

ClinicalTrials.gov

Source last updated

Mar 06, 2019

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT01652690

Title

Prospective Observational Study to Describe Characteristics and Management of Patients With Postmenopausal Osteoporosis Treated With Prolia® in Routine Clinical Practice

Sponsor

Amgen

Status

COMPLETED

Phase

Observational

Condition raw

Osteoporosis, Postmenopausal

Condition normalized

Osteoporosis, Postmenopausal

Modality raw

Osteoporosis, Postmenopausal

Modality normalized

monoclonal antibody

Target raw

Denosumab (Prolia®)

Target normalized

Denosumab (Prolia®)

Interventions

Denosumab

Public preview

Source record

This study aimed to characterize the management of postmenopausal osteoporosis patients treated with denosumab in routine clinical practice across the Czech Republic and Slovakia. It involved 600 participants and focused on treatment adherence and safety data over a 24-month period.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Prospective Observational Study to Describe Characteristics and Management of Patients With Postmenopausal Osteoporosis Treated With Prolia® in Routine Clinical Practice

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT01652690

Status

COMPLETED

Phase

Observational

Sponsor

Amgen

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedMar 06, 2019

Internal syncJun 05, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01652690

Indication

Osteoporosis, Postmenopausal

Modality

monoclonal antibody

Target

Denosumab (Prolia®)

Intervention

Denosumab

Source record